ARRDC3 and esophageal squamous cell carcinoma: In addition, treatment with protease inhibitor MG-132 did not lead to any significant changes in YAP expression in the miR-624 mimic + oe-NC- or miR-624 mimic + oe-ARRDC3-treated ESCC cells (Supplementary Figure 1b, c), suggesting that MG-132 inhibits the degradation of YAP by ARRDC3.